The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated massive gains, the lapse of its patent opened the floodgates to generic competitors, dramatically eroding market share. This presents a unique dilemma for pharmaceutical companies depending on related blockbuster pr

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, producing billions in revenue , its exclusivity period created a deluge of generic competition , significantly impacting its position . While specific businesses may try to capitalize on male sexual dysfunction, the existing